Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074605 · ClinicalTrials.gov registry record
Cognitive Effects of Interferon in Patients With Melanoma
A clinical trial, sponsored by University of Arizona.
- Completed
- Registry status
- 36
- Enrollment target
NCT02074605: Completed study, sponsored by University of Arizona.
NCT02074605 is a clinical trial that has completed, run by University of Arizona. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02074605 has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
Interferon alpha is the only approved adjuvant biologic therapy for individuals diagnosed with high risk malignant melanoma (stage 2 or 3). There is evidence that interferon has some adverse cognitive effects on patients, but there are limited data. The investigators hypothesis is that compared to patients with melanoma who do not receive interferon, patients who have melanoma and are treated with interferon will show an objective decrease in performance on neurocognitive assessment. This study will enroll patients with melanoma who qualify for interferon, and either decide to undergo interferon treatment or choose watchful waiting instead. All patients will be assessed with a cognitive testing battery twice. Observation patients will undergo testing at their first appointment in which they consent to the study, as well as at their next physician visit, approximately 3 months from the first visit. Interferon patients will be tested immediately prior to starting interferon, as well as immediately after completing high dose interferon.
Primary Outcome
Cognitive function as assessed by a brief neurocognitive testing battery
Interventions
- BIOLOGICAL Interferon alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-05 |
What the finished NCT02074605 record still lists
NCT02074605 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Interferon alpha is the first listed.
NCT02074605 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02074605 about?
NCT02074605 is a clinical study titled "Cognitive Effects of Interferon in Patients With Melanoma". Interferon alpha is the only approved adjuvant biologic therapy for individuals diagnosed with high risk malignant melanoma (stage 2 or 3). There is evidence that interferon has some adverse cognitive effects on patients, but there are limited data. The investigators hypothesis is that compared to p...
What is the current status of trial NCT02074605?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2008-07. Estimated completion is 2010-05.
What interventions are being tested in trial NCT02074605?
The interventions under investigation include: Interferon alpha (BIOLOGICAL).
Who is sponsoring clinical trial NCT02074605?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia